Last reviewed · How we verify
Standard of Care IV antihypertensive
Standard of Care IV antihypertensive is a ACE inhibitor Small molecule drug developed by The Medicines Company. It is currently in Phase 3 development for Hypertension. Also known as: nitroglycerin, nicardipine, sodium nitroprusside, isosorbide dinitrate.
Blocks the action of angiotensin II at its receptor, leading to vasodilation and decreased blood pressure.
Blocks the action of angiotensin II at its receptor, leading to vasodilation and decreased blood pressure. Used for Hypertension.
At a glance
| Generic name | Standard of Care IV antihypertensive |
|---|---|
| Also known as | nitroglycerin, nicardipine, sodium nitroprusside, isosorbide dinitrate, hydralizine |
| Sponsor | The Medicines Company |
| Drug class | ACE inhibitor |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the inhibition of the angiotensin II type 1 receptor, which is a key component of the renin-angiotensin-aldosterone system. By blocking this receptor, the drug reduces the vasoconstrictive and aldosterone-secreting effects of angiotensin II, resulting in decreased blood pressure and reduced strain on the heart.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Intravenous Administration of Vitamin B Complex Improves Renal Recovery in Patients With AKI (PHASE4)
- Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF (PHASE3)
- Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes. (PHASE4)
- Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of Care IV antihypertensive CI brief — competitive landscape report
- Standard of Care IV antihypertensive updates RSS · CI watch RSS
- The Medicines Company portfolio CI
Frequently asked questions about Standard of Care IV antihypertensive
What is Standard of Care IV antihypertensive?
How does Standard of Care IV antihypertensive work?
What is Standard of Care IV antihypertensive used for?
Who makes Standard of Care IV antihypertensive?
Is Standard of Care IV antihypertensive also known as anything else?
What drug class is Standard of Care IV antihypertensive in?
What development phase is Standard of Care IV antihypertensive in?
What are the side effects of Standard of Care IV antihypertensive?
What does Standard of Care IV antihypertensive target?
Related
- Drug class: All ACE inhibitor drugs
- Target: All drugs targeting AT1 receptor
- Manufacturer: The Medicines Company — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Also known as: nitroglycerin, nicardipine, sodium nitroprusside, isosorbide dinitrate, hydralizine
- Compare: Standard of Care IV antihypertensive vs similar drugs
- Pricing: Standard of Care IV antihypertensive cost, discount & access